The pharmaceutical company Endo International on Thursday announced a $50 million settlement with the New York Attorney General's Office and Suffolk and Nassau counties, removing another defendant from New York's sprawling opioid trial, which began in June on Long Island.

Endo and its subsidiaries, including Endo Pharmaceuticals and Par Pharmaceuticals, has agreed to pay $22.3 million to the attorney general's office and $13.85 million to each of the counties to resolve the suit, in which the government officials alleged that the companies were in part responsible for the opioid crisis.

Endo, which is based in Malvern, Pennsylvania, has admitted no fault or wrongdoing. The trial will continue with the remaining defendants, including Teva Cephalon and Allergan Finance.